Astagraf XL Approval History
- FDA approved: Yes (First approved July 19th, 2013)
- Brand name: Astagraf XL
- Generic name: tacrolimus
- Company: Astellas Pharma US, Inc.
- Treatment for: Organ Transplant, Rejection Prophylaxis
Astagraf XL (tacrolimus) is a calcineurin-inhibitor immunosuppressant for the prophylaxis of organ rejection in patients receiving a kidney transplant.
Development History and FDA Approval Process for Astagraf XL
|Jul 22, 2013||Astellas Announces FDA Approval of Astagraf XL (tacrolimus extended-release capsules) for the Prophylaxis of Organ Rejection|
|Dec 26, 2005||NDA for Immunosuppressant FK506 Modified Release Formulation Submitted in the US|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.